— Round led by Versant Ventures with participation from founding investor Novo Holdings and new investors SR One, Dawn Biopharma and Pictet– –Entering Phase I testing for next-generation weight loss therapy by antagonizing GIPR– COPENHAGEN, Denmark, Dec. 4, 2024 /PRNewswire/ — Antag…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.